Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia vi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Virol
Main Authors: Kibler, Karen V., Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L., Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C., Tomaras, Georgia D., Roederer, Mario, Foulds, Kathryn E., Forthal, Donald N., Seaman, Michael S., Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, Cristillo, Anthony D., Weiss, Deborah, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L., Esteban, Mariano, Wagner, Ralf, Pantaleo, Giuseppe, Jacobs, Bertram L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2019
Assuntos:
Vaccines and Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6340019/
https://ncbi.nlm.nih.gov/pubmed/30429340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01513-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados